Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA rejects Qutenza in HIV-PN; NeurogesX slashes workforce by 57%

This article was originally published in Scrip

Executive Summary

The news of the US FDA's rejection of NeurogesX's Qutenza (capsaicin 8%) patch as a therapy to manage HIV-associated peripheral neuropathy (HIV-PN) not only affected the San Mateo, California-based firm's shares on 8 March – which fell 20%, or 13 cents, to close at 53 cents – but also the company's workforce, which is being slashed by 57%.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC016565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel